912461-47-3Relevant academic research and scientific papers
Increasing selectivity of CC chemokine receptor 8 antagonists by engineering nondesolvation related interactions with the intended and off-target binding sites
Shamovsky, Igor,De Graaf, Chris,Alderin, Lisa,Bengtsson, Malena,Bladh, H?kan,B?rjesson, Lena,Connolly, Stephen,Dyke, Hazel J.,Van Den Heuvel, Marco,Johansson, Henrik,Josefsson, Bo-G?ran,Kristoffersson, Anna,Linnanen, Tero,Lisius, Annea,M?nnikk?, Roope,Nordén, Bo,Price, Steve,Ripa, Lena,Rognan, Didier,Rosendahl, Alexander,Skrinjar, Marco,Urbahns, Klaus
supporting information; experimental part, p. 7706 - 7723 (2010/07/04)
The metabolic stability and selectivity of a series of CCR8 antagonists against binding to the hERGion channel and cytochrome Cyp2D6 are studied by principal component analysis. It is demonstrated that an efficient way of increasing metabolic stability an
NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES
-
Page/Page column 23, (2010/11/24)
The invention provides compounds of general formula. (II) wherein R and R?1? are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES
-
Page/Page column 22-23, (2008/06/13)
The invention provides compounds of general formula. [Chemical formula should be inserted here. Please see paper copy] (II) wherein R and R1 are as defined in the specification, processes for their preparation, pharmaceutical compositions conta
NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES
-
Page/Page column 27; 28, (2008/06/13)
The invention provides compounds of general formula wherein R and R1 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
